Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Consolid Equity in connection with the establishment of Road Mobility Services Group
Mandate

Vinge advises Consolid Equity in connection with the establishment of Road Mobility Services Group

September 13, 2024 M&A Commercial Agreements Banking and Finance Employment and Benefits Real Estate and Construction Automotive, Mobility and Electrification

Vinge has advised Consolid Equity Investment AB (“Consolid Equity”) in connection with the establishment of the Road Mobility Services Group through the consolidation of 28 tire and towing companies.

By combining the expertise and resources of 28 leading local tire and towing companies, Road Mobility Services Group creates a new leading Nordic service partner for both commercial and private customers. Consolid Equity acts as a strategic partner in the new group.

Vinge's team consisted primarily of responsible partners Christina Kokko and Johanna Wiberg together with Viktor Lennartsson, Per Kling, Ellen Flygt, Olof Löfvenberg, Madelene Andersson and Matilda Hamner (M&A); Martin Boström and Elis Allmark (Commercial Agreements); Calle Tengwall and Josef Groow (Banking and Finance); Hanna Marberg and Tyra von Mentzer (Employment); Agnes Pigg and Hanna Kövamees (Real Estate) and Ellinore Boström Andersson and Diana Kanold (Transaction Support Specialists).

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026